Ethan Munzinger, MD
Cardiovascular Disease · Searcy, ARNPI 1427343185
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (51.1%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Penumbra, Inc. at 38.4% of the total. Reporting peaked in 2022 at $7,249 and has fallen 94.1% since, to $425 in 2025.
Across 212 payments — averaging $108.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$9K
- Medtronic$8K
- Cardiovascular Systems Inc.$2K
- Abbott$689
- Avinger Inc.$635
- Boston Scientific$615
- plus $3K from 26 others
What the payments were for
- Speaking & faculty fees$4,80021%
- Travel & lodging$11,74751%
- Food & beverage$6,45728%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 12 | $8,841 |
| Medtronic(2 entities) | 72 | $7,991 |
| Cardiovascular Systems Inc. | 16 | $1,529 |
| Abbott | 10 | $689 |
| Avinger Inc. | 16 | $635 |
| Boston Scientific | 18 | $615 |
| Shockwave Medical, Inc | 12 | $512 |
| Bard Peripheral Vascular, Inc. | 2 | $511 |
| Acist Medical Systems, Inc. | 2 | $221 |
| Inari Medical, Inc. | 5 | $221 |
| Abiomed | 3 | $204 |
| Philips North America LLC | 6 | $203 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $135 |
| Amgen | 6 | $108 |
| Mimedx Group, Inc. | 1 | $81 |
| Tactile Systems Technology Inc | 1 | $73 |
| Novartis | 2 | $48 |
| Livanova USA, Inc. | 2 | $45 |
| Koya Medical, Inc. | 1 | $45 |
| Baxter Healthcare | 1 | $44 |
| Sanofi-aventis U.S. LLC | 3 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Nipro Medical Corporation | 1 | $26 |
| Johnson & Johnson | 2 | $24 |
| Merck | 1 | $24 |
| Cordis US CORP. | 1 | $19 |
| Cardiva Medical, Inc. | 1 | $18 |
| Heartflow, Inc. | 1 | $16 |
| Irhythm Technologies, Inc. | 1 | $16 |
| Cook Medical LLC | 1 | $13 |
| Pfizer | 1 | $12 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$8,783
- HawkOne$2,802
- ADVISA DR MRI SURESCAN$2,035
- Diamondback Peripheral$1,181
- Adapta$973
- Xience V coronary stent system$509
- VENOVO$488
- ClosureFast$483
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$261
- PANTHERIS$258
- CVI SYSTEMS$155
- IVUS Systems$147
- IN.PACT Admiral$134
- FLOWTRIEVER CATHETER, S$122
- CT THROMBECTOMY SYSTEM KIT$122
- Impella$116
- ROTABLATOR$101
How this compares
$23,004 in reported general payments places this provider in the 85th percentile of 130 cardiovascular disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 55 | $49,871 |
| XareltoRivaroxaban | 58 | $39,876 |
| EntrestoSacubitril/Valsartan | 23 | $23,704 |
| BrilintaTicagrelor | 14 | $7,795 |
| NexlizetBempedoic Acid/Ezetimibe | 13 | $5,235 |
| Ezetimibe | 120 | $1,983 |
| Clonidine | 15 | $1,410 |
| Metoprolol Succinate | 112 | $1,281 |
| Rosuvastatin Calcium | 121 | $1,085 |
| Eplerenone | 14 | $1,037 |
| Atorvastatin Calcium | 100 | $866 |
| ClopidogrelClopidogrel Bisulfate | 86 | $786 |
| Losartan Potassium | 51 | $469 |
| Cilostazol | 13 | $323 |
| Spironolactone | 52 | $244 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $12 | $49,87155 claims |
| Johnson & JohnsonXarelto | $24 | $39,87658 claims |
| NovartisEntresto | $48 | $23,70423 claims |
| AstraZenecaBrilinta | $12 | $7,79514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 130 cardiovascular disease providers in Arkansas.
Other cardiovascular disease in Searcy
- Ian CawichLittle Rock$294K
- Barry TedderJonesboro$130K
- Harvinder DodEl Dorado$126K
- William RollefsonLittle Rock$74K
- Andre PaixaoLittle Rock$73K
- Julio SchwarzFort Smith$70K
- Maximiliano ArroyoJonesboro$46K
- Wesley LaneLittle Rock$46K
- Omar QaqishLittle Rock$45K
- Dharmendra PatelJonesboro$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.